Latest Breaking News On - Etranacogene dezaparvovec - Page 8 : comparemela.com
uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
uniQure Inc : uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NantKwest Stock Goes North, uniQure s HOPE-B Trial On Hold, EU Greenlights First COVID-19 Vaccine
NEW YORK CITY (dpa-AFX) - Today s Daily Dose brings you news about NantKwest s non-muscle invasive bladder cancer trial results and the company s proposed merger with privately-held ImmunityBio; Agios sale of oncology portfolio to Servier for $1.8 billion upfront; the clinical hold on uniQure s hemophilia B gene therapy program due to safety concerns; ChemoCentryx ACCOLADE trial results; and the first COVID-19 vaccine authorized in the EU.
Read on.
1. Agios Sells Oncology Portfolio for $1.8 Bln Upfront
Agios Pharmaceuticals Inc. (AGIO) is all set to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company, for up to $2.0 billion in cash.
uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
Company to hold conference call today at 8:30 a.m. ET
LEXINGTON, Mass. and AMSTERDAM, Dec. 21, 2020 (GLOBE NEWSWIRE) uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its hemophilia B gene therapy program, including the pivotal, Phase III HOPE-B study, has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). Patient dosing is complete in each of uniQure’s three hemophilia B gene therapy studies, and there is no plan to enroll or treat additional patients.